Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumors
Interventions
RADIATION

Stereotactic Body Radiotherapy (SBRT)

SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.

DRUG

navoximod

A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.

DRUG

NLG802 (indoximod Prodrug)

An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Lumos Pharma

INDUSTRY

lead

Luke, Jason, MD

OTHER